The article discusses the importance of considering debt when assessing a company’s risk, as stated by Charlie Munger, a renowned investor. Li Lu, a fund manager backed by Berkshire Hathaway, emphasizes that the biggest investment risk is not price volatility, but the potential for permanent loss of capital, often caused by debt. The article then examines the debt levels of NATCO Pharma Limited, an Indian pharmaceutical company.<\/p>\n
As of September 2025, NATCO Pharma had \u20b92.53 billion in debt, up from \u20b92.01 billion a year ago. However, the company also has \u20b932.0 billion in cash, resulting in a net cash position of \u20b929.5 billion. The company’s liabilities, including short-term and long-term debt, total \u20b917.0 billion, which is offset by its cash and receivables valued at \u20b917.3 billion.<\/p>\n
The article concludes that NATCO Pharma’s debt levels are manageable, given its significant cash reserves and ability to generate free cash flow. The company’s free cash flow over the past three years has been around 63% of its earnings before interest and tax (EBIT), which is a normal level. This suggests that NATCO Pharma is in a good position to pay down debt when necessary.<\/p>\n
While the company’s debt levels are not a major concern, the article notes that falling earnings could potentially make its debt more risky. The company’s EBIT declined by 32% over the last year, which could impact its ability to maintain a healthy balance sheet.<\/p>\n
Overall, the article suggests that NATCO Pharma’s debt levels are not a significant concern, given its strong cash position and ability to generate free cash flow. However, investors should continue to monitor the company’s earnings and debt levels to ensure that they remain manageable. The article also notes that there are other risks associated with investing in NATCO Pharma, including two warning signs that investors should be aware of.<\/p>\n
In conclusion, the article provides a detailed analysis of NATCO Pharma’s debt levels and financial position, highlighting the importance of considering debt when assessing a company’s risk. While the company’s debt levels are manageable, investors should remain vigilant and monitor the company’s earnings and debt levels to ensure that they remain healthy.<\/p>\n","protected":false},"excerpt":{"rendered":"
The article discusses the importance of considering debt when assessing a company’s risk, as stated by Charlie Munger, a renowned investor. Li Lu, a fund manager backed by Berkshire Hathaway, emphasizes that the biggest investment risk is not price volatility, but the potential for permanent loss of capital, often caused by debt. The article then […]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","fifu_image_url":"","fifu_image_alt":"","_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[24,2],"tags":[],"class_list":["post-89666","post","type-post","status-publish","format-standard","hentry","category-natco","category-pharma"],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"jetpack-related-posts":[{"id":89762,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/07\/the-high-court-has-asked-novo-nordisk-to-respond-to-natcos-request-to-cancel-its-patent\/","url_meta":{"origin":89666,"position":0},"title":"The High Court has asked Novo Nordisk to respond to Natco’s request to cancel its patent.","author":"Team Small News","date":"January 7, 2026","format":false,"excerpt":"The Delhi High Court has ordered Novo Nordisk, a Danish pharmaceutical company, to respond to a petition filed by Natco Pharma, a Hyderabad-based company, seeking to revoke the patent on the diabetes and anti-obesity drug semaglutide. The patent, which is set to expire in March, has been a subject of\u2026","rel":"","context":"In "Natco"","block_context":{"text":"Natco","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/natco\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89898,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/02\/03\/glenmark-pharmaceuticals-sets-sights-on-fy28-for-debut-of-oncology-drugs-and-expansion-of-profit-margins-reports-etpharma\/","url_meta":{"origin":89666,"position":1},"title":"Glenmark Pharmaceuticals sets sights on FY28 for debut of oncology drugs and expansion of profit margins, reports ETPharma.","author":"Team Small News","date":"February 3, 2026","format":false,"excerpt":"Glenmark Pharmaceuticals, a leading Indian pharmaceutical company, has expressed confidence that its cancer drug, Trastuzumab Rezetecan (SHR-A1811), will enter licensed markets by FY28, driving an improvement in both gross and EBITDA margins. The company has guided for an EBITDA margin of 23% for the ongoing fiscal year and expects its\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89821,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/19\/sun-pharma-sets-sights-on-10-billion-organon-takeover-to-bolster-us-presence\/","url_meta":{"origin":89666,"position":2},"title":"Sun Pharma Sets Sights on $10 Billion Organon Takeover to Bolster US Presence","author":"Team Small News","date":"January 19, 2026","format":false,"excerpt":"Sun Pharmaceutical Industries Ltd., India's largest drug manufacturer, is considering a monumental acquisition of Organon, a US-based company specializing in women's health and biosimilars. The potential deal, valued at $10 billion, is being led by the company's founder, Dilip Shanghvi. If successful, this acquisition would be a significant milestone for\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/sun-pharma-logo.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":89682,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/18\/glenmark-secures-1-billion-deal-for-multi-regional-rights-to-hansoh-pharmas-cancer-treatment-medication\/","url_meta":{"origin":89666,"position":3},"title":"Glenmark secures $1 billion deal for multi-regional rights to Hansoh Pharma’s cancer treatment medication.","author":"Team Small News","date":"December 18, 2025","format":false,"excerpt":"Glenmark Specialty S.A., a subsidiary of India-based Glenmark Pharmaceuticals, has entered into a licensing agreement with China's Jiangsu Hansoh Pharmaceutical Group Co. for the oncology drug Aumolertinib. The agreement grants Glenmark exclusive rights to develop and commercialize Aumolertinib in several high-potential markets, including the Middle East, Africa, Southeast and South\u2026","rel":"","context":"In "Glenmark"","block_context":{"text":"Glenmark","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/glenmark\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89791,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2026\/01\/12\/aurobindo-pharma-acquires-khandelwal-labs-non-cancer-portfolio-for-%e2%82%b9325-crore\/","url_meta":{"origin":89666,"position":4},"title":"Aurobindo Pharma Acquires Khandelwal Labs’ Non-Cancer Portfolio for \u20b9325 Crore.","author":"Team Small News","date":"January 12, 2026","format":false,"excerpt":"Aurobindo Pharma, a leading Indian pharmaceutical company, has acquired the non-oncology business of Khandelwal Laboratories for \u20b9325 crore. The acquisition is a strategic move by Aurobindo Pharma to expand its product portfolio and strengthen its position in the domestic market. Khandelwal Laboratories is a Mumbai-based pharmaceutical company that operates in\u2026","rel":"","context":"In "Aurobindo Pharma"","block_context":{"text":"Aurobindo Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/aurobindo-pharma\/"},"img":{"alt_text":"","src":"","width":0,"height":0},"classes":[]},{"id":89660,"url":"https:\/\/smallnews.in\/pharmaceuticals\/2025\/12\/13\/does-piramal-pharma-limited-possess-sustainable-competitive-advantages-for-sustained-long-term-expansion-analyzing-earnings-trends-capitalizing-on-exceptional-growth-opportunities\/","url_meta":{"origin":89666,"position":5},"title":"Does Piramal Pharma Limited Possess Sustainable Competitive Advantages for Sustained Long-Term Expansion – Analyzing Earnings Trends & Capitalizing on Exceptional Growth Opportunities","author":"Team Small News","date":"December 13, 2025","format":false,"excerpt":"Piramal Pharma Limited, a leading pharmaceutical company, has been exhibiting remarkable growth patterns, making it an attractive investment opportunity. To determine if the company has competitive moats for long-term growth, it's essential to analyze its earnings growth patterns and market trends. Piramal Pharma has demonstrated a strong track record of\u2026","rel":"","context":"In "Pharma"","block_context":{"text":"Pharma","link":"https:\/\/smallnews.in\/pharmaceuticals\/category\/pharma\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/smallnews.in\/pharmaceuticals\/wp-content\/uploads\/sites\/6\/2025\/05\/Piramal-Healthcare.jpg?resize=350%2C200&ssl=1","width":350,"height":200},"classes":[]}],"_links":{"self":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/comments?post=89666"}],"version-history":[{"count":0,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/posts\/89666\/revisions"}],"wp:attachment":[{"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/media?parent=89666"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/categories?post=89666"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallnews.in\/pharmaceuticals\/wp-json\/wp\/v2\/tags?post=89666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}